Avenue Therapeutics, Inc. (ATXI) Insider Trading Activity
NASDAQ$0.2201
Market Cap
$693,249.00
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
388 of 877
Rank in Industry
223 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ATXI Insider Trading Activity
ATXI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $1,250 | 2 | 50 |
Sells | $183 | 2 | 50 |
Related Transactions
| KRANZLER JAY D | director | 2 | $1,250 | 1 | $137 | $1,113 |
| Herskowitz Neil | director | 0 | $0 | 1 | $46 | $-46 |
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Insider Activity of Avenue Therapeutics, Inc.
Over the last 12 months, insiders at Avenue Therapeutics, Inc. have bought $1,250 and sold $183 worth of Avenue Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Avenue Therapeutics, Inc. have bought $187,842 and sold $628,961 worth of stock each year.
Highest buying activity among insiders over the last 12 months: KRANZLER JAY D (director) — $1,250.
The last purchase of 497 shares for transaction amount of $1,243 was made by KRANZLER JAY D (director) on 2024‑09‑30.
List of Insider Buy and Sell Transactions, Avenue Therapeutics, Inc.
| 2024-12-02 | Sale | Herskowitz Neil | director | 23 0.0012% | $2.00 | $46 | -35.57% | |
| 2024-11-05 | Sale | KRANZLER JAY D | director | 61 0.0043% | $2.24 | $137 | -39.64% | |
| 2024-09-30 | KRANZLER JAY D | director | 497 0.037% | $2.50 | $1,243 | -33.33% | ||
| 2024-09-27 | KRANZLER JAY D | director | 3 0.0002% | $2.40 | $7 | -32.67% | ||
| 2023-12-11 | Sale | Davidow Robert L | 10 percent owner | 617,000 4.9094% | $0.14 | $86,560 | -64.66% | |
| 2023-09-08 | Fortress Biotech, Inc. | 10 percent owner | 418,410 4.9086% | $0.72 | $301,255 | -80.60% | ||
| 2023-09-08 | ROSENWALD LINDSAY A MD | director | 348,675 4.0905% | $0.72 | $251,046 | -80.60% | ||
| 2022-10-11 | Sale | InvaGen Pharmaceuticals, Inc. | director | 388,888 48.3396% | $7.71 | $3M | -59.86% | |
| 2021-09-15 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 7,160 0.042% | $1.62 | $11,599 | -69.05% | |
| 2021-05-06 | Herskowitz Neil | director | 2,500 0.0142% | $3.99 | $9,975 | -68.56% | ||
| 2020-08-20 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 3,840 0.0235% | $12.13 | $46,579 | -60.88% | |
| 2020-03-10 | Vazzano Joseph Walter | Chief Financial Officer | 1,889 0.0115% | $7.94 | $14,999 | +12.63% | ||
| 2020-03-09 | Vazzano Joseph Walter | Chief Financial Officer | 1,500 0.0093% | $7.99 | $11,983 | +13.49% | ||
| 2020-02-27 | Herskowitz Neil | director | 2,400 0.0139% | $8.20 | $19,680 | +3.72% | ||
| 2020-02-26 | Herskowitz Neil | director | 161 0.001% | $8.73 | $1,406 | +0.45% | ||
| 2020-02-25 | Herskowitz Neil | director | 10,000 0.0629% | $9.31 | $93,100 | -0.89% | ||
| 2020-02-25 | Vazzano Joseph Walter | Chief Financial Officer | 1,200 0.0074% | $9.09 | $10,908 | -0.89% | ||
| 2019-09-12 | Ingram Elizabeth Garrett | director | 16,000 0.0982% | $6.27 | $100,320 | +46.39% | ||
| 2019-08-09 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 2,375 0.0138% | $5.56 | $13,205 | +49.32% | |
| 2019-08-08 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 2,313 0.0141% | $5.62 | $12,999 | +55.35% |
Total: 46
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| KRANZLER JAY D | director | 559 0.0177% | $123.04 | 2 | 1 | |
| Herskowitz Neil | director | 97 0.0031% | $21.35 | 18 | 1 | |
| Fortress Biotech, Inc. | 10 percent owner | 1032390 32.7774% | $227,229.04 | 1 | 0 | <0.0001% |
| ROSENWALD LINDSAY A MD | director | 354318 11.2493% | $77,985.39 | 11 | 0 | <0.0001% |
| Paley Jeffrey | director | 79663 2.5292% | $17,533.83 | 2 | 0 | |
| Vazzano Joseph Walter | Chief Financial Officer | 65252 2.0717% | $14,361.97 | 3 | 4 | |
| Davidow Robert L | 10 percent owner | 22000 0.6985% | $4,842.20 | 0 | 1 | |
| Ingram Elizabeth Garrett | director | 16000 0.508% | $3,521.60 | 1 | 0 | |
| InvaGen Pharmaceuticals, Inc. | director | 0 0% | $0 | 0 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$13,665,147 | 42 | -70.74% | $2.72M | |
$1,138,733 | 28 | -4.94% | $4.44M | |
$41,829 | 26 | -15.60% | $2.17M | |
$193,112 | 22 | -20.59% | $1.77M | |
$1,616,354 | 20 | -12.22% | $3.7M | |
$613,181 | 18 | -20.90% | $2.79M | |
$960,082 | 17 | -6.29% | $4.3M | |
$1,556,551 | 15 | -25.43% | $4.32M | |
$111,212 | 12 | -28.79% | $3.02M | |
$139,855 | 11 | -32.84% | $3.81M | |
$4,146,041 | 11 | -40.86% | $1.29M | |
$309,830 | 10 | -55.78% | $4.08M | |
$100,375 | 8 | -51.85% | $3.56M | |
$37,067 | 3 | -89.81% | $3.29M | |
$1,057,000 | 3 | 5.27% | $3.7M | |
$37,465 | 3 | -40.67% | $2.85M | |
$165,600 | 2 | -3.58% | $3M | |
Avenue Therapeutics, Inc. (ATXI) | $552,301 | 2 | -80.60% | $693,249.00 |
$739,010 | 1 | 3.33% | $4.27M |
ATXI Institutional Investors: Active Positions
| Increased Positions | 6 | +60% | 184,227 | +98.76% |
| Decreased Positions | 5 | -50% | 178,131 | -95.5% |
| New Positions | 2 | New | 181,089 | New |
| Sold Out Positions | 4 | Sold Out | 178,070 | Sold Out |
| Total Postitions | 11 | +10% | 192,627 | +3.27% |
ATXI Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ikarian Capital, Llc | $35.00 | 4.67% | 140,000 | +140,000 | New | 2024-12-31 |
| Boothbay Fund Management, Llc | $10.00 | 1.37% | 41,089 | +41,089 | New | 2024-12-31 |
| Ubs Group Ag | $2.00 | 0.26% | 7,920 | +1,777 | +28.93% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.1% | 3,096 | +1,356 | +77.93% | 2024-12-31 |
| Wells Fargo & Company/Mn | $0 | 0.02% | 500 | -61 | -10.87% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | 0% | 14 | +4 | +40% | 2024-12-31 |
| Emfo, Llc | $0 | 0% | 8 | +<1 | +14.29% | 2024-06-30 |
| Jpmorgan Chase & Co | $0 | 0% | 0 | <1 | Sold Out | 2024-12-31 |
| Sabby Management, Llc | $0 | 0% | 0 | -63,060 | Sold Out | 2024-12-31 |
| Armistice Capital, Llc | $0 | 0% | 0 | -115,000 | Sold Out | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.